Feasibility of a Multi-omics Platform for Hematological Malignancies

This is a biological study based on a collaborative effort involving several Italian haematology centres (including the coordinating centre). The study will be conducted retrospectively and prospectively using bone marrow (BM) or peripheral blood (PB) samples, lymph node or tissue biopsies with metastatic involvement, and other biological fluids, such as cerebrospinal fluid and pathological pleural effusion.

NCT Number	NCT07445438
Lead Sponsor	Azienda Ospedaliero-Universitaria di Parma
Conditions	Myeloma Multiple, Chronic Leukemia, Acute Leukemia, Myeloproliferative Disorders, Lymphoproliferative Disorders, Myelodysplastic Disorders
Enrollment	1,040 participants
Start Date	2025-03-31
Primary Completion	2030-03 (estimated)
Study Completion	2030-03 (estimated)
Updated on ClinicalTrials.gov	2026-03-03